… and generative models improve protein-ligand prediction and de-novo molecule … growth driven by IT-pharma synergy, generic drugmakers, and agile biotech startups … AI-enabled drug discovery market represents a transformational opportunity for pharmaceutical R …

… Channel Modulators HSK16149, a novel ligand for the α2-δ subunit of … Similarly, mirogabalin, another α2-δ subunit ligand, produced significant pain relief versus … , drug-disease interactions, and cost analysis of regimens. Building a trusting pharmacist …

… “disease-target-drug” network.20–24 As such, network pharmacology offers a … .gov) and were used as ligand files for molecular docking. The … . Lower binding energies indicate stronger ligand-receptor interactions and higher stability …

… -third of all licensed drugs. Investigating these important cell … , Professor and Chair of Pharmacology Andreas Bock, Ph.D., … of the Institute of Pharmacology at the University Medical … drugs with few side effects. Publication details Romy Thomas et al, Ligand …

… critical for clinicians, researchers, and pharmaceutical stakeholders. The report provides insights … . Interesting facts: Unlike chemotherapy, immunotherapy drugs work by mobilizing the immune … (CTLA-4), programmed cell death ligand 1 (PD-L1), and lymphocyte …

… importance and pharmacological relevance, the precise mechanisms dictating ligand-dependent G … implications for drug discovery, as they suggest that tailoring ligand structure … rational design of next-generation drugs targeting these pivotal receptors …

… drugs for metabolic diseases. But after meeting with some pharma … company, Ligand Pharmaceuticals, to not only license five drugs, but … by storm. Led by pharmaceutical giants Novo (which … Medical StartupsBy Amy FeldmanForbesThis Pharma Company Is Betting Big …

… of big pharma companies to sign a drug pricing agreement … GlobalData, parent company of Pharmaceutical Technology, previously noted that … Trump to reduce drug prices. Now, Regeneron Pharmaceuticals is the only … rights to its programmed death ligand 1 (PD-1) …

… activator of nuclear factor-κB ligand (RANKL) and is widely used … biosimilar “demonstrated equivalent efficacy and pharmacodynamics and similar immunogenicity and safety … comparable options that may reduce drug spending while preserving outcomes. If …

Sanofi is excited for 2026. At the JP Morgan Healthcare conference, several upcoming catalyst events were highlighted, including high-profile read-outs, regulatory submissions, and regulatory decisions. Among these, one that will be keenly watched is Phase …